FarEye Launches Grow – A Game-changing Self-Serve Merchant Portal for Logistics Companies to Accelerate Customer Acquisition and Drive Growth
11.5.2023 17:00:00 EEST | Business Wire | Press release
FarEye today announced Grow, a solution for logistic companies to provide a modern-age experience to its customers. With a user-friendly interface, frictionless onboarding, automated booking, and seamless payments integration, Grow is set to empower logistics businesses to accelerate customer acquisition, improve customer satisfaction, and drive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005538/en/
Grow is a cutting-edge self-serve merchant portal designed to revolutionize the way logistics companies manage their shipping operations. (Photo: Business Wire)
With the parcel delivery market projected to hit $200 billion by 2026 and over tens of millions of shippers worldwide, it's clear that logistic companies have an unprecedented opportunity for growth. Every retailer and e-commerce company wants to offer home delivery but continues to struggle to find the right, modern-age logistics partner and are stuck with legacy ways of home delivery. Grow enables logistics companies to address this demand-supply gap.
"We are thrilled to launch Grow, which we believe will become an indispensable tool for logistics companies seeking to acquire new retailers and stay ahead of the competition," said Kushal Nahata, CEO of FarEye. "Our team has worked tirelessly to create a platform that unlocks the potential of thousands of logistic companies, and we are confident that Grow will transform the way logistics businesses interact with their customers and manage their day-to-day operations."
FarEye Grow is an easy way for merchants to self-serve, get quotes, create orders, generate labels, and manage transactions. It also offers shipment-level visibility and in-built exception management, enabling retailers and shippers to save time and effort, leading to increased customer satisfaction. In addition, automated invoice generation and payments with digital wallet capabilities allow logistic companies to reduce payment delays and improve cash flow. Grow is equipped with built-in plug-ins with major e-commerce platforms like Shopify and BigCommerce, allowing shippers to connect and start delivering quickly.
FarEye Grow is a part of the FarEye product portfolio that supports companies through the complete order-to-door delivery journey. It has products like Ship, Track, Route, Execute, Experience, Analyze, and now, Grow, which offers the following key benefits:
- Personalized portal for easy onboarding: Allows self-onboarding and complete order entry, get quotes, generate labels, real-time status updates, and proof of delivery on one platform.
- Track and trace visibility: Provides real-time track and trace visibility and address validation to merchants for booked orders.
- Scale with your merchants: Track merchants’ growth, run campaigns based on orders and transactions, and make recommendations for merchants to transact more for revenue and business growth.
- Booking order transparency: Self-service merchant order booking directly from the platform, this helps CEPs track revenue and reduce lost revenue.
- Digital wallet management: Offer customers purchase credit for their shipping needs. Provide complete visibility into all transactions, book and pay for shipments by multiple payment modes, including directly by wallet.
FarEye's Grow is the ultimate customer portal for CEP companies looking to streamline shipping operations, expand their customer network, and achieve sustainable growth in today's competitive industry. To learn more about the portal and how it can benefit your business, visit the FarEye website today.
About FarEye
FarEye’s Delivery Management platform turns deliveries into a competitive advantage. Retail, e-commerce and third-party logistics companies use FarEye’s unique combination of orchestration, real-time visibility, and branded customer experiences to simplify complex last-mile delivery logistics. The FarEye platform allows businesses to increase consumer loyalty and satisfaction, reduce costs and improve operational efficiencies. FarEye has 150+ customers across 30 countries and five offices globally. FarEye, First Choice for Last Mile.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005538/en/
Contact information
PR Contact:
Bradford Peirce, Industry Strategy Executive, bradford.peirce@fareye.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom